Series
Newleos Therapeutics Launches with $93.5M to Advance Novel Neuropsychiatric Treatments
Newleos Therapeutics, mental health, neuropsychiatry, Roche assets, Series A funding, anxiety disorders, substance use disorders, GABA modulators
Delaware Court Ruling Paves Way for Aurion Biotech IPO, Alcon to Appeal Decision
Aurion Biotech, Alcon Research, IPO, Delaware Court of Chancery, reverse stock split, voting proxy, Series C consent rights
Retro Biosciences, Backed by Sam Altman, Seeks $1 Billion to Extend Human Lifespan by 10 Years
Retro Biosciences, Sam Altman, Human Lifespan Extension, Biotechnology, Series A Funding, Artificial Intelligence in Healthcare
Hinge Bio Secures $30 Million Series A’ Financing for Next-Generation Therapies via GEM-DIMER Platform
Hinge Bio, immune reset, GEM-DIMER platform, Series A’ financing, autoimmune diseases, HB2198, Systemic Lupus Erythematosus
Umoja Biopharma Advances In Situ CAR-T Therapy with FDA Clearance and $100M Series C Funding
Umoja Biopharma, CAR-T therapy, in situ, UB-VV111, FDA clearance, hematologic malignancies, Series C funding
Light Horse Therapeutics Secures $62M Series A Funding and Partners with Novartis for Cancer Therapies
Light Horse Therapeutics, Novartis, Series A funding, cancer therapies, small molecule therapeutics, precision genetic editing platform
Orbis Medicines Secures €90 Million Series A Funding to Revolutionize Oral Macrocycle Drug Discovery
Orbis Medicines, Series A funding, oral macrocycle drugs, nCycles, biologic drug alternatives, pharmaceutical innovation
Orbis Kicks Off 2025 with €90M Series A Funding in Fierce Biotech Fundraising Tracker
Fierce Biotech Fundraising Tracker 2025, Orbis Series A Funding, Biotech Venture Capital, 2025 Biotech Investments, Series A Funding Rounds
SiteOne Therapeutics Secures $100M Series C Funding to Advance Non-Opioid Pain Treatments
Non-opioid pain treatments, SiteOne Therapeutics, Series C funding, ion channel modulators, peripheral nervous system (PNS), sensory hyperexcitability disorders.
Angitia Biopharmaceuticals Secures $120 Million in Series C Funding to Develop Novel Musculoskeletal Treatments
Angitia Biopharmaceuticals, Series C funding, Musculoskeletal diseases, Osteoporosis, Osteogenesis imperfecta (OI), Spinal fusion, Bispecific antibodies, Clinical development